untitled design

Pfizer / BioNTech Vaccine: High protection in the 12-18 age group

The vaccine of Pfizer /BioNTech against coronavirus has been shown to be 93% effective in preventing hospitalization for the disease in the elderly 12 to 18 years old, according to a study released by the Centers for Disease Control and Prevention (CDC) – the main public health service in the US – today, Tuesday.

It is noted that this study was conducted over time between June and September, when the highly contagious was predominant Delta mutation of the virus.

However, data from 19 pediatric hospitals showed that among them 179 of patients treated with Covid-19, the 97% it was unvaccinated, in yet another assurance of the efficacy of the preparation.

From 16%, approximately, patients treated with severe form of Covid-19 in need of mechanical support, no one he was not vaccinated, Reuters reports.

It is worth mentioning that the CDC report is based on clinical tests performed by companies in this age group that showed a high immune response to the virus, although these trials were not designed to demonstrate efficacy against hospitalization.

It is recalled that the Pfizer / BioNTech vaccine is approved for use in children from 12 years and companies apply for licenses for use in older children from five years.

US Food and Drug Administration Expert Advisory Group (FDA) is expected to weigh the data on vaccination in young children later this month.

CDC data «strengthen “The importance of vaccination to protect young Americans from severe forms of Covid-19,” the study authors concluded.

You may also like

Get the latest

Stay Informed: Get the Latest Updates and Insights

 

Most popular